Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792392 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2021.09.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data.
Cancers (Basel)
February 2025
Department of Medical and Surgical Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy.
The advent of Janus kinase (JAK) inhibitors, including tofacitinib, filgotinib, and upadacitinib, has significantly widened the therapeutic options for patients with inflammatory bowel disease (IBD). These agents offer the advantage of oral administration and have demonstrated efficacy in inducing and maintaining remission. However, concerns regarding their safety have emerged, particularly concerning cardiovascular and infectious complications, which appear more pronounced in patients with pre-existing risk factors such as older age, smoking, or comorbidities.
View Article and Find Full Text PDFAdvances in the treatment of polymyalgia rheumatica.
Rheumatology (Oxford)
March 2025
Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy.
Polymyalgia rheumatica (PMR) is a common inflammatory disorder affecting individuals over 50. The cornerstone of PMR treatment remains oral glucocorticoids (GCs), with initial doses tailored to the risk of relapse and comorbidities. However, relapses occur in up to 76% of cases, and long-term GC use is associated with significant toxicity, affecting up to 85% of patients.
View Article and Find Full Text PDFNew and future perspectives in Behçet's syndrome.
Arch Rheumatol
December 2024
Department of Internal Medicine, Division of Rheumatology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye.
Behçet's syndrome is a variable vessel vasculitis characterized by a diverse range of clinical manifestations resulting from inflammation involving several organs and systems. While significant progress has been made in understanding the pathogenesis and treatment of Behçet's syndrome, challenges remain in achieving optimal disease control and preventing long-term complications. This review explores recent advances in the management of Behçet's syndrome, with a focus on emerging therapies and future directions.
View Article and Find Full Text PDFRecent advancements in understanding the potential pathogenesis of prurigo nodularis (PN) have paved the way for the development of new, targeted therapies. Emerging evidence suggests that JAK inhibitors may provide a safe and effective treatment option for both atopic and non-atopic PN. Here, we present a case of refractory PN successfully treated with tofacitinib.
View Article and Find Full Text PDFShort-term efficacy of tofacitinib, a JAK inhibitor, in IFIH1-related Aicardi-Goutières syndrome.
Eur J Med Genet
March 2025
Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, 110004, China. Electronic address:
Aicardi-Goutières syndrome (AGS) is a genetically heterogeneous type-I interferonopathy presenting in infancy with intracranial calcifications, white matter lesions, and brain atrophy. AGS7, caused by gain-of-function (GOF) mutations in the IFIH1 gene, triggers excessive type-I interferon production, leading to autoimmune responses. We describe an 18-year-old female diagnosed with AGS7 due to a somatic GOF mutation in IFIH1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!